Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

European shares fall as pharma stocks come under fire; Richemont rallies

Published 04/11/2016, 10:04
Updated 04/11/2016, 10:10
© Reuters. Traders work at their desks in front of the German share price index DAX board in Frankfurt
LLY
-
MRK
-
CFR
-
OREP
-
SASY
-
NOVOb
-
HIK
-
FLTRF
-
UBIP
-
JCDX
-
STOXX
-

By Danilo Masoni

MILAN (Reuters) - European shares fell on Friday, weighed down by weaker drugmakers after two U.S. lawmakers called on federal antitrust regulators to open a probe for possible price fixing.

A slew of earnings updates also delivered a mixed picture.

The U.S. lawmakers on Thursday called for a probe into whether Sanofi (PA:SASY), Eli Lilly (N:LLY), Merck (N:MRK) and Novo Nordisk (CO:NOVOb) colluded to set prices for insulin and other diabetes drugs. Sanofi and Novo Nordisk were down 1.6 and 2.9 percent respectively.

Top faller was Hikma (L:HIK), down 7 percent after HSBC cut its price target citing broader market concerns over a separate U.S. Department of Justice investigation into price collusion in the pharma market.

The sector has been hit recently by worries that Hillary Clinton could seek tougher pricing regulation if she wins the race for the White House.

"A Clinton victory could be unhelpful for health care stocks," Citi analysts said in a strategy note.

The pan-European STOXX 600 index (STOXX) was down 1 percent and on track for its biggest weekly fall since February. The index has been hit by growing nervousness before the U.S. presidential election.

"As the presidential election race appears to (be) getting tighter with only a few days left until Americans are going to the polls many traders continuing to reduce their risk exposure further which is also weighing on stocks," Markus Huber, trader at City of London Markets said in a note.

Elsewhere market action was driven by earnings updates.

France's Richemont (S:CFR) rose 6 percent after the luxury goods group announced a management revamp after sales and core net profit in the six months to September, hit by one-off restructuring charges and product buy-backs.

Helvea analyst Andreas von Arx said the key figures were above expectations while other analyst welcomed management comments that sales in October were modestly positive. The company had issued a profit warning in September.

Among outstanding gainers, Ubisoft (PA:UBIP) soared 9.5 percent, topping STOXX gainers, as Kepler Cheuvreux upgrade the French game developer to "buy" after the company lifted its operating profit target.

Shares were bosted at Cosmetics giant L'Oreal (PA:OREP), whose sales growth beat expectations, and gambling firm Paddy Power (I:PPB), which lifted its full-year profit forecast citing a boost in the sterling value of its euro revenue, this year's merger and favourable sporting results.

© Reuters. Traders work at their desks in front of the German share price index DAX board in Frankfurt

But French outdoor advertising company JC Decaux (PA:JCDX) fell 7.3 percent after it said organic revenue growth would turn negative in the final quarter of the year and affect margins.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.